---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-26-000007"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:26:48.928676+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amphastar Q4 revenue $183.1M, down 1.8% YoY; GAAP EPS $0.51 vs $0.74

## Summary
- Full year 2025 net revenue $719.9M, down 1.6% YoY from $732.0M.
- GAAP net income Q4 $24.4M ($0.51 diluted EPS) vs $38.0M ($0.74) in Q4 2024; FY $98.1M ($2.03) vs $159.5M ($3.06).
- Adjusted non-GAAP net income Q4 $34.2M ($0.73 diluted EPS) vs $47.2M ($0.92) a year ago.
- CEO cites BAQSIMI double-digit growth and FDA approvals of iron sucrose and teriparatide injections as positives.
- Three novel peptides and a synthetic corticotropin compound added to pipeline for oncology, ophthalmology, and immunology.

## SEC filing metadata
- accession: 0001297184-26-000007
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000007/0001297184-26-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000007/amph-20260226x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-26-000007
- JSON: https://secwatch.observer/filing/0001297184-26-000007.json
- Plain text: https://secwatch.observer/filing/0001297184-26-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.